U.S. Wireless Telecom Stock News

Context for CrowdStrike Holdings (CRWD) Investors CrowdStrike Holdings (CRWD) shares have been moving without a clear single news catalyst, which can make recent performance and valuation feel harder to interpret for you as an investor. Over the past month, the stock shows a return of about a 5.7% decline, with a roughly 4.9% decline over the past 3 months and a small gain year to date. That mix of short term weakness and a positive 1 year total return of about 26.8% raises natural questions...

Earlier this month, Teladoc Health launched nationwide enhancements to its long-running 24/7 Care virtual urgent care service, expanding treatable conditions, integrating specialist consults, using claims and Health Information Exchange data for preventive care, and enabling real-time prescription benefit checks. A distinctive aspect of this update is the use of integrated data and on-the-spot specialist input to resolve most issues within a single visit while prompting many patients to act...

Madrigal’s new Pfizer partnership puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a clinical-stage oral DGAT-2 inhibitor. This agreement directly targets future combination approaches in metabolic liver disease. The deal centers on DGAT-2’s role in triglyceride assembly and liver fat storage, an area closely linked to inflammation in MASH. Investors now have a new data point to watch as...

Terns Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining progress across its pipeline programs. Investor attention has centered on interim Phase 1 CARDINAL ASH data for TERN-701, which points to a potentially best-in-class profile with encouraging deep molecular responses. Next, we’ll examine how the promising TERN-701 Phase 1 CARDINAL data shapes Terns Pharmaceuticals’ investment narrative and future development...

TransDigm Group (TDG) caught investor attention after reporting Q3 revenue of US$2.44b, exceeding analyst expectations by 1.6%, and surpassing internal guidance for fiscal 2025 revenue and EBITDA, according to management. See our latest analysis for TransDigm Group. The latest earnings surprise appears to have reinforced an already strong run, with a 10.2% 1 month share price return and a 13.96% 3 month share price return, alongside a 1 year total shareholder return of 17.64% that sits within...

If you are wondering whether Fiserv's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. Fiserv shares last closed at US$67.50, with returns of a 1.8% decline over 7 days, a 2.1% decline over 30 days, a 2.9% gain year to date, and declines of 67.0% over 1 year, 34.6% over 3 years and 38.2% over 5 years. Recent headlines around Fiserv have focused on its role as a major provider of payments and financial...

Recently, Acadia Healthcare reiterated its 2025 revenue guidance of US$3.28 billion to US$3.30 billion while flagging a US$25 million to US$30 million EBITDA headwind from a new New York Medicaid policy restricting reimbursement for out-of-state behavioral health care. This policy change highlights Acadia’s sensitivity to state-level Medicaid decisions and the operational and earnings pressure that reimbursement shifts can create. We’ll now examine how the New York Medicaid reimbursement...

Woodward recently received an upgrade to a Zacks Rank #1 (Strong Buy), reflecting improved earnings estimates that analysts interpret as a sign of strengthening business conditions. This upgrade places Woodward in the top tier of Zacks-covered companies for earnings estimate revisions, highlighting growing analyst conviction around its underlying performance outlook. We’ll now examine how this Zacks upgrade, built on improving earnings estimates, could influence Woodward’s existing...

First Watch Restaurant Group (FWRG) has put expansion at the center of its latest update, reporting record preliminary 2025 operational results that include 64 new restaurants across 23 states, as well as same-restaurant sales and traffic growth. See our latest analysis for First Watch Restaurant Group. The strong preliminary 2025 update and fresh Boston opening come after a mixed share price pattern, with a 7.81% year to date share price return but a 10.77% decline in 1 year total...

Event context and recent performance Science Applications International (SAIC) has been drawing attention after recent share price moves, with the stock last closing at $108.06. That has come alongside modest annual revenue and net income growth. Over the past month, SAIC shares show a 6.38% return, with the past 3 months at 11.54% and year to date at 6.76%. The 1 year total return stands at a 5.63% decline. See our latest analysis for Science Applications International. SAIC’s recent 11.54%...

GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches and data partnerships. See our latest analysis for GeneDx Holdings. Despite a sharp 1 day share price return of 4.8% decline and a 30 day share price return of 26.2% decline that suggest sentiment has cooled after the guidance update, the 1 year total shareholder return of 53.2% and a very large...

Recently, Oakmark Funds highlighted Gartner, Inc. as a global research leader and disclosed that it had been buying shares after AI-related worries pressured the stock. At the same time, Gartner outlined nine future of work trends centered on AI’s impact on employees and HR, underscoring its role as both an advisor on, and subject of, AI-driven change. We’ll now examine how renewed fund-manager confidence in Gartner’s resilience to AI disruption may influence the company’s existing...

Recent analyst upgrades and increased confidence in Colgate-Palmolive (CL), tied to early growth signals in emerging markets and lower reliance on the US, have renewed attention on how the stock is currently priced. See our latest analysis for Colgate-Palmolive. The recent analyst upgrades, alongside a series of rating revisions across the street, appear to have coincided with stronger trading interest. Colgate-Palmolive’s 7 day share price return of 9.68% and year to date share price return...

IPG Photonics (IPGP) is back in focus after reporting strong third quarter results tied to electric vehicle and stationary battery welding demand, as well as launching its IPG Defense unit headquarters in Huntsville, Alabama. See our latest analysis for IPG Photonics. The recent quarterly update and expansion into defense have arrived after a 90 day share price return decline of 10.28% and a 5 year total shareholder return decline of 69.12%, which suggests long term momentum has been weak...

What J. M. Smucker’s recent returns suggest right now With no single headline event driving attention to J. M. Smucker (SJM), many investors are looking at the stock’s recent performance, valuation metrics, and fundamentals to understand how it currently stacks up. See our latest analysis for J. M. Smucker. Recently, J. M. Smucker’s share price return has picked up, with a 1-day move of 2.68% and a 7-day gain of 9.27%, while its 1-year total shareholder return of 8.02% comes against a weaker...

American Tower (AMT) is back in focus after its CoreSite unit rolled out native 400G AWS Direct Connect at the Chicago data center campus, targeting high-bandwidth, low-latency needs for AI and data-heavy enterprise workloads. See our latest analysis for American Tower. Despite the CoreSite news and earlier commentary around EchoStar related risks for tower operators, American Tower’s 1-day share price return of 2.02% and 7-day share price return of 4.75% contrast with a 90-day share price...

B. Riley Securities downgraded Triumph Financial (TFIN) from Buy to Neutral, citing valuation concerns and typical first quarter seasonal caution. The stock fell 3.4% as the share price approached US$70. See our latest analysis for Triumph Financial. Despite the downgrade and recent pullback, Triumph Financial’s short term momentum remains firm, with a 30 day share price return of 10.94% and a 90 day gain of 34.67%. This contrasts with a 1 year total shareholder return decline of 24.58%, but...

Earlier this month, Okta, Inc. announced a new share repurchase program of up to US$1,000 million of its Class A common stock, to be funded from existing cash and operating cash flow, while also presenting its outlook at the Needham Growth Conference. Alongside this capital return plan, Okta launched a beta Digital ID Verification capability and received supportive analyst commentary pointing to its expanding role in identity security. Next, we’ll explore how the new US$1,000 million buyback...

Why Vericel’s latest guidance is drawing fresh attention Vericel (VCEL) has put out preliminary, unaudited guidance pointing to 23% revenue growth for the fourth quarter, roughly US$276 million in 2025 net revenue, and GAAP profitability for a second straight year. See our latest analysis for Vericel. Vericel’s latest guidance lands after a mixed share price performance, with a 7 day share price return of a 7.48% decline, a 90 day share price return of 7.42%, and a 1 year total shareholder...

Why Marsh & McLennan Companies (MRSH) is on investors’ radar today Marsh & McLennan Companies (MRSH) continues to draw attention as investors review how its professional services and insurance solutions business lines align with recent share performance and fundamentals, even though there has not been a single headline event driving the move. The stock has returned 0.3% over the past week and is roughly flat year to date. It has shown a 2.2% decline over the past month and a 1.7% decline over...

Preliminary Q1 Revenue Update Puts Twist Bioscience in Focus Twist Bioscience (TWST) drew investor attention after announcing preliminary, unaudited revenue for its first fiscal quarter ended December 31, 2025, ahead of full results scheduled for release on February 2, 2026. See our latest analysis for Twist Bioscience. The preliminary Q1 revenue update lands after a strong recent run in the stock, with a 30 day share price return of 28.84% and a 90 day share price return of 30.18%. However,...

In the latest session, HCI Group underperformed the broader market as investors looked ahead to its upcoming earnings release, which is expected to show very large year-on-year earnings-per-share growth. With analyst estimate revisions holding steady and the company trading on a forward price-to-earnings multiple slightly above its industry average, the focus is firmly on whether HCI’s results justify current expectations for its business performance. We’ll now explore how this...

Winnebago Industries recently made a major showing at the Florida RV SuperShow in Tampa, unveiling new models and features across its Winnebago, Grand Design RV and Newmar brands, including the Sunflyer Class C RV, Thrive lightweight travel trailer, Grand Design’s Foundation 42GD destination trailer and Newmar’s Freedom Aire Compact C coach. This concentrated wave of product launches highlights how Winnebago is broadening its reach across motorized and towable segments, giving investors...

In early January 2026, the New York Stock Exchange, part of Intercontinental Exchange, announced that its NYSE Arca and NYSE American markets will become the U.S. options listing venues for major MSCI benchmarks, including the MSCI Emerging Markets, EAFE, ACWI, World, and USA indexes, pending regulatory approval. These expanded derivatives listings, alongside fresh ESG analytics contracts in Sweden’s premium pension system, highlight how MSCI’s indices and sustainability data are being...